Completed PHASE4 INTERVENTIONAL 2-arm NCT02621905

Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg

Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions

Sponsor: Mayne Pharma International Pty Ltd

Conditions Neutropenia

Interventions Lozanoc Sporanox

Updated 8 times since 2017 Last updated: Oct 24, 2018 Started: Nov 30, 2015 Primary completion: Nov 30, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Neutropenia, this trial is completed. The trial is conducted by Mayne Pharma International Pty Ltd and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Nov 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Aug 2018 — Nov 2018 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE4
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayne Pharma International Pty Ltd

Data source: Mayne Pharma International Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Darlinghurst, Australia